Atriva reaches a development milestone and receives an additional tranche of running seed financing to develop its influenza therapeutic to clinical stage

The next generation of Antiviral Therapies: Co-Led by Stichting Participatie Atriva and High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received a second tranche of its running seed financing in total of € 3 Mn from Dutch, German and Canadian investors, after lead compound ATR-002 (Atriva’s antiviral MEK-Inhibitor against Influenza) has passed an important preclinical milestone paving the way to clinical development stage.


New Image Video of ATRIVA available!

A new image video of ATRIVA has been created, highlighting the imporant features of our approach against Influenza and other viral diseases.

Don't miss this opportunity to get to know ATRIVA a bit better and listen to our CSO, Prof. Oliver Planz, and our CEO, Dr. Rainer Lichtenberger, by watching the video on the newspage.

Here you can start the video by clicking on it.


ATRIVA scientists present MEK inhibitor technology at International Conference of Antiviral Research in Atlanta

Atriva scientists were invited to give an overview talk on their antiviral MEK inhibitor concept at the 30th International Conference of Antiviral Research (ICAR2017) that was held from May 21-25, 2017, in Atlanta/Georgia.

The annual ICAR is the most important conference series in the antiviral research field and gathers experts from academia and the industry.


Interview with ATRIVA CEO during BIO-Europe Spring(R) 2017

During the BIO-Europe Spring (R) event 2017, ATRIVA's CEO Dr. Rainer Lichtenberger was interviewed about the aims and future of ATRIVA.

You can watch the video on the newspage by clicking on it!


New paper published about anti-influenza activity of CI-1040

Our scientific founders published a new paper on antiviral action of MEK inhbitors in Antiviral Research, the highest-ranking journal in the area of antiviral therapy and the fourth-highest in the general field of virology.